Ranopto
Ranibizumab biosimilar developed by Teva Canada. Reference product Lucentis.
Brands by market: Ranopto (Canada) · Commercial partner or holder: Teva Canada
FDAnot listed
EMAnot listed
PMDAnot listed
HCOct 2023approved
CDSCOnot listed
EDEnot listed
Status by market
FDA
United States
Not listed by FDA.
EMA
European Union
Not listed by EMA.
PMDA
Japan
Not listed by PMDA.
HC
Canada · Ranopto
Health CanadaApprovedBrand
Ranopto
Holder or applicant
Teva Canada Limited
Pathway
Biosimilar biologic drug (Notice of Compliance)
Approved
Oct 2023
Application or permission
DIN 02542250
Presentations
10 mg
Source
S022
CDSCO
India
Not listed by CDSCO.
EDE
United Arab Emirates
Not listed by EDE.
Chronology
- HCOct 2023Notice of Compliance, Health Canada
Sources
Planning ranibizumab biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.